Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent ...

Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.51%, the company may face hurdles ...

Debt Management: Gilead Sciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to ...

Market sentiment is bullish as it awaits the Federal Reserve's announcement of potential rate cuts tomorrow, October 29. The ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

• PayPal Holdings (NASDAQ: PYPL) is expected to report quarterly earnings at $1.20 per share on revenue of $8.24 billion. • NeoGenomics (NASDAQ: NEO) is projected to report quarterly loss at $0.01 per ...

Biotech company Regeneron (NASDAQ:REGN) reported in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its ...